Analyst Ratings for Harpoon Therapeutics
Analysts have provided the following ratings for Harpoon Therapeutics (NASDAQ:HARP) within the last quarter:
Harpoon Therapeutics And Roche To Collaborate On Clinical Trials To Study Novel Immuno-Oncology Combination For Small Cell Lung Cancer
Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Harpoon Therapeutics Presents Preclinical Data For TriTAC-XR Platform That Supports Potential For Improved Safety By Minimizing Cytokine Release Syndrome
Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American
Citigroup Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $7
Citigroup analyst Yigal Nochomovitz maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $14 to $7.